Apremilast (Otezla, Celgene) resulted in a greater reduction in the number of oral ulcers associated with Behçet’s syndrome than placebo, say researchers recently writing in the New England Journal of Medicine.
On Friday, the U.S. Food and Drug Administration approved apremilast (Otezla, Celgene) for the treatment of oral ulcers associated with Behçet’s disease, a rare, chronic, multisystem inflammatory condition that affects approximately five in 100,000 people in the U.S.
A new set of treatment guidelines for Paget’s disease have been published leading with recommendations for the use of bisphosphonates.
Will you recognize Behçet disease when you see it?
Yutiq (fluocinolone acetonide intravitreal implant) for Chronic Non-Infectious Posterior Segment Uveitis Gets FDA Nod
The approval is based on data from two randomized, sham injection-controlled, double-masked phase 3 clinical trials with patient follow-up for 3 years.
Mepolizumab gets the nod for the rare disease formerly known as Churg-Strauss syndrome.
In this case study, Dr. Litvin presents a complicated case of neuromyelitis optica (Devic’s disease), a rare inflammatory autoimmune CNS disease affecting the spinal cord and optic nerves.
Adalimumab for the treatment of noninfectious uveitis has advantages over no treatment or conventional treatment with steroid therapy.
In this story, we revisit the clinical trials that led to the approval of adalimumab for uveitis.
Adalimumab improves function and quality of life for patients with uveitis, shows a study presented at 2015 ACR/ARHP.